theragenomics: biomarkers

thasso has prepared for you the overview table “theragenomic biomarkers” in context of their medications, indications, affected patient subgroups, and pertinent drug label sections.  The basis for this product is the list of accepted biomarkers as published by the FDA. Drugs are linked to the according drug labels accessible in Drugs@FDA.

* Please note that in this table, the active pharmacological ingredient (API) is listed; brand names may vary considerably, that is trade names for drugs approved outside the US may differ from those found within the US, as may the names of generics, both within and outside the US. In case of doubt, searching for the API in the first place would be a good idea.

 

Active pharmalocical ingredient (API)


Therapeutic
Area/Indication*


Biomarker†


Referenced
Subgroup / Phenotype‡


According Labeling
Sections


Abacavir


Infectious
Diseases


HLA-B


HLA-B*5701
allele carriers


Boxed
Warning, Contraindications, Warnings and Precautions


Ado-Trastuzumab
Emtansine


Oncology


ERBB2


HER2
protein overexpression or gene amplification positive


Indications
and Usage, Warnings and Precautions, Adverse Reactions, Clinical
Pharmacology, Clinical Studies


Afatinib


Oncology


EGFR


EGFR
exon 19 deletion or exon 21 substitution (L858R) positive


Indications
and Usage, Dosage and Administration, Adverse Reactions, Clinical
Pharmacology, Clinical Studies


Alectinib


Oncology


ALK


ALK
gene rearrangement positive


Indications
and Usage, Adverse Reactions, Clinical Pharmacology, Clinical
Studies


Alirocumab


Endocrinology


LDLR


LDL
receptor mutation heterozygotes


Indications
and Usage, Adverse Reactions, Clinical Studies


Amitriptyline


Psychiatry


CYP2D6


CYP2D6
poor metabolizers


Precautions


Anastrozole


Oncology


ESR1,
PGR


Hormone
receptor positive


Indications
and Usage, Adverse Reactions, Drug Interactions, Clinical Studies


Arformoterol
(1)


Pulmonary


UGT1A1


UGT1A1
poor metabolizers


Clinical
Pharmacology


Arformoterol
(2)


Pulmonary


CYP2D6


CYP2D6
intermediate or poor metabolizers


Clinical
Pharmacology


Aripiprazole


Psychiatry


CYP2D6


CYP2D6
poor metabolizers


Dosage
and Administration, Use in Specific Populations, Drug
Interactions, Clinical Pharmacology


Aripiprazole
Lauroxil


Psychiatry


CYP2D6


CYP2D6
poor metabolizers


Dosage
and Administration, Use in Specific Populations, Clinical
Pharmacology


Arsenic
Trioxide


Oncology


PML-RARA


PML-RARα
translocation positive


Clinical
Pharmacology, Indications and Usage


Atomoxetine


Psychiatry


CYP2D6


CYP2D6
poor metabolizers


Dosage
and Administration, Warnings and Precautions, Drug Interactions,
Clinical Pharmacology


Azathioprine


Rheumatology


TPMT


TPMT
intermediate or poor metabolizers


Clinical
Pharmacology, Warnings, Precautions, Drug Interactions, Adverse
Reactions, Dosage and Administration


Belinostat


Oncology


UGT1A1


UGT1A1*28
allele homozygotes


Dosage
and Administration, Clinical Pharmacology


Blinatumomab


Oncology


BCR-ABL1


Philadelphia
chromosome negative


Indications
and Usage, Clinical Studies


Boceprevir


Infectious
Diseases


IFNL3


IL28B
rs12979860 T allele carriers (C/T and T/T genotype)


Clinical
Pharmacology


Bosutinib


Oncology


BCR-ABL1


Philadelphia
chromosome positive


Indications
and Usage, Adverse Reactions, Use in Specific Populations,
Clinical Studies


Brexpiprazole


Psychiatry


CYP2D6


CYP2D6
poor metabolizers


Dosage
and Administration, Drug Interactions, Use in Specific
Populations, Clinical Pharmacology


Busulfan


Oncology


BCR-ABL1


Philadelphia
chromosome negative


Clinical
Studies


Cabozantinib


Oncology


RET


RET
mutation positive


Clinical
Studies


Capecitabine


Oncology


DPYD


DPD
deficient


Warnings
and Precautions, Patient Counseling Information


Carbamazepine
(1)


Neurology


HLA-B


HLA-B*1502
allele carriers


Boxed
Warning, Warnings, Precautions


Carbamazepine
(2)


Neurology


HLA-A


HLA-A*3101
allele carriers


Warnings


Carglumic
Acid


Inborn
Errors of Metabolism


NAGS


N-acetylglutamate
synthase deficient


Indications
and Usage, Warnings and Precautions, Use in Specific Populations,
Clinical Pharmacology, Clinical Studies


Carisoprodol


Rheumatology


CYP2C19


CYP2C19
poor metabolizers


Use
in Specific Populations, Clinical Pharmacology


Carvedilol


Cardiology


CYP2D6


CYP2D6
poor metabolizers


Drug
Interactions, Clinical Pharmacology


Celecoxib


Rheumatology


CYP2C9


CYP2C9
poor metabolizers


Dosage
and Administration, Use in Specific Populations, Clinical
Pharmacology


Ceritinib


Oncology


ALK


ALK
gene rearrangement positive


Indications
and Usage, Adverse Reactions, Clinical Pharmacology, Clinical
Studies


Cetuximab
(1)


Oncology


EGFR


EGFR
protein expression positive


Indications
and Usage, Dosage and Administration, Warnings and Precautions,
Adverse Reactions, Clinical Pharmacology, Clinical Studies


Cetuximab
(2)


Oncology


KRAS


KRAS
codon 12 and 13 mutation negative


Indications
and Usage, Dosage and Administration, Warnings and Precautions,
Adverse Reactions, Clinical Pharmacology, Clinical Studies


Cevimeline


Dental


CYP2D6


CYP2D6
poor metabolizers


Precautions


Chloroquine


Infectious
Diseases


G6PD


G6PD
deficient


Precautions


Chlorpropamide


Endocrinology


G6PD


G6PD
deficient


Precautions


Cholic
Acid


Inborn
Errors of Metabolism


AKR1D1,
HSD3B7, CYP27A1, AMACR, CYP7A1


Bile
acid synthesis enzyme deficient


Indications
and Usage, Warnings and Precautions, Adverse Reactions, Use in
Specific Populations, Clinical Pharmacology, Clinical Studies


Cisplatin


Oncology


TPMT


TPMT
intermediate or poor metabolizers


Adverse
Reactions


Citalopram
(1)


Psychiatry


CYP2C19


CYP2C19
poor metabolizers


Clinical
Pharmacology, Warnings, Dosage and Administration


Citalopram
(2)


Psychiatry


CYP2D6


CYP2D6
poor metabolizers


Clinical
Pharmacology


Clobazam


Neurology


CYP2C19


CYP2C19
poor metabolizers


Dosage
and Administration, Use in Specific Populations, Clinical
Pharmacology


Clomipramine


Psychiatry


CYP2D6


CYP2D6
poor metabolizers


Precautions


Clopidogrel


Cardiology


CYP2C19


CYP2C19
intermediate or poor metabolizers


Boxed
Warning, Dosage and Administration, Warnings and Precautions,
Clinical Pharmacology


Clozapine


Psychiatry


CYP2D6


CYP2D6
poor metabolizers


Dosage
and Administration, Use in Specific Populations, Clinical
Pharmacology


Cobimetinib


Oncology


BRAF


BRAF
V600E/K mutation positive


Indications
and Usage, Dosage and Administration, Adverse Reactions, Clinical
Pharmacology, Clinical Studies


Codeine


Anesthesiology


CYP2D6


CYP2D6
ultrarapid metabolizers


Boxed
Warning, Warnings and Precautions, Use in Specific Populations,
Patient Counseling Information


Crizotinib


Oncology


ALK


ALK
gene rearrangement positive


Indications
and Usage, Dosage and Administration, Adverse Reactions, Clinical
Pharmacology, Clinical Studies


Dabrafenib
(1)


Oncology


BRAF


BRAF
V600E/K mutation positive


Indications
and Usage, Dosage and Administration, Warnings and Precautions,
Adverse Reactions, Clinical Pharmacology, Clinical Studies,
Patient Counseling Information


Dabrafenib
(2)


Oncology


G6PD


G6PD
deficient


Warnings
and Precautions, Adverse Reactions, Patient Counseling Information


Dapsone
(1)


Dermatology


G6PD


G6PD
deficient


Warnings
and Precautions, Use in Specific Populations, Patient Counseling
Information


Dapsone
(2)


Infectious
Diseases


G6PD


G6PD
deficient


Precautions,
Adverse Reactions, Overdosage


Dasatinib


Oncology


BCR-ABL1


Philadelphia
chromosome positive, T315I mutation positive


Indications
and Usage, Dosage and Administration, Warnings and Precautions,
Adverse Reactions, Clinical Pharmacology, Clinical Studies


Denileukin
Diftitox


Oncology


IL2RA


CD25
antigen positive


Indications
and Usage, Warnings and Precautions, Clinical Studies


Desipramine


Psychiatry


CYP2D6


CYP2D6
poor metabolizers


Precautions


Dexlansoprazole


Gastroenterology


CYP2C19


CYP2C19
poor metabolizers


Drug
Interactions, Clinical Pharmacology


Dextromethorphan
and Quinidine


Neurology


CYP2D6


CYP2D6
poor metabolizers


Warnings
and Precautions, Clinical Pharmacology


Diazepam


Neurology


CYP2C19


CYP2C19
poor metabolizers


Clinical
Pharmacology


Dinutuximab


Oncology


MYCN


MYCN
amplification positive


Clinical
Studies


Dolutegravir


Infectious
Diseases


UGT1A1


UGT1A1
poor metabolizers


Clinical
Pharmacology


Doxepin
(1)


Psychiatry


CYP2D6


CYP2D6
poor metabolizers


Clinical
Pharmacology


Doxepin
(2)


Psychiatry


CYP2C19


CYP2C19
poor metabolizers


Clinical
Pharmacology


Drospirenone
and Ethinyl Estradiol


Gynecology


CYP2C19


CYP2C19
intermediate metabolizers


Clinical
Pharmacology


Eliglustat


Inborn
Errors of Metabolism


CYP2D6


CYP2D6
ultrarapid, intermediate or poor metabolizers


Indications
and Usage, Dosage and Administration, Contraindications, Warnings
and Precautions, Drug Interactions, Use in Specific Populations,
Clinical Pharmacology, Clinical Studies


Elosulfase


Inborn
Errors of Metabolism


GALNS


N-acetylgalactosamine-6-sulfatase
deficient


Indications
and Usage, Warnings and Precautions, Use in Specific Populations,
Clinical Pharmacology, Clinical Studies


Eltrombopag
(1)


Hematology


F5


Factor
V Leiden carriers


Warnings
and Precautions


Eltrombopag
(2)


Hematology


SERPINC1


Antithrombin
III deficient


Warnings
and Precautions


Erlotinib
(1)


Oncology


EGFR


EGFR
protein expression positive


Clinical
Studies


Erlotinib
(2)


Oncology


EGFR


EGFR
exon 19 deletion or exon 21 substitution (L858R) positive


Indications
and Usage, Dosage and Administration, Adverse Reactions, Clinical
Pharmacology, Clinical Studies


Escitalopram
(1)


Psychiatry


CYP2D6


CYP2D6
poor metabolizers


Drug
Interactions


Escitalopram
(2)


Psychiatry


CYP2C19


CYP2C19
poor metabolizers


Adverse
Reactions


Esomeprazole


Gastroenterology


CYP2C19


CYP2C19
poor metabolizers


Drug
Interactions, Clinical Pharmacology


Everolimus
(1)


Oncology


ERBB2


HER2
protein overexpression negative


Indications
and Usage, Dosage and Administration, Warnings and Precautions,
Adverse Reactions, Drug Interactions, Use in Specific Populations,
Clinical Pharmacology, Clinical Studies


Everolimus
(2)


Oncology


ESR1


Estrogen
receptor positive


Clinical
Studies


Evolocumab


Endocrinology


LDLR


LDL
receptor mutation heterozygotes and homozygotes


Indications
and Usage, Dosage and Administration, Adverse Reactions, Use in
Specific Populations, Clinical Studies


Exemestane
(1)


Oncology


ESR1


Estrogen
receptor positive


Indications
and Usage, Dosage and Administration, Clinical Studies


Exemestane
(2)


Oncology


PGR


Progesterone
receptor positive


Clinical
Studies


Fesoterodine


Urology


CYP2D6


CYP2D6
poor metabolizers


Drug
Interactions, Clinical Pharmacology


Fluorouracil
(1)


Dermatology


DPYD


DPD
deficient


Contraindications,
Warnings


Fluorouracil
(2)


Oncology


DPYD


DPD
deficient


Warnings


Fluoxetine


Psychiatry


CYP2D6


CYP2D6
poor metabolizers


Warnings
and Precautions, Drug Interactions, Clinical Pharmacology


Flurbiprofen


Rheumatology


CYP2C9


CYP2C9
poor metabolizers


Clinical
Pharmacology


Fluvoxamine


Psychiatry


CYP2D6


CYP2D6
poor metabolizers


Drug
Interactions


Fulvestrant


Oncology


ESR1,
PGR


Hormone
receptor positive


Indications
and Usage, Clinical Pharmacology, Clinical Studies


Galantamine


Neurology


CYP2D6


CYP2D6
poor metabolizers


Clinical
Pharmacology


Gefitinib


Oncology


EGFR


EGFR
exon 19 deletions or exon 21 substitution (L858R) mutation
positive


Indications
and Usage, Dosage and Administration, Clinical Pharmacology,
Clinical Studies


Glimepiride


Endocrinology


G6PD


G6PD
deficient


Warnings
and Precautions, Adverse Reactions


Glipizide


Endocrinology


G6PD


G6PD
deficient


Precautions


Glyburide


Endocrinology


G6PD


G6PD
deficient


Precautions


Hydralazine


Cardiology


NAT1-2


NAT
1-2 slow acetylators


Clinical
Pharmacology


Ibrutinib


Oncology


del
(17p)


Chromosome
17p deletion positive


Indications
and Usage, Clinical Studies


Iloperidone


Psychiatry


CYP2D6


CYP2D6
poor metabolizers


Dosage
and Administration, Warnings and Precautions, Drug Interactions,
Clinical Pharmacology


Imatinib
(1)


Oncology


KIT


KIT
protein expression positive, c-KIT D816V mutation negative


Indications
and Usage, Dosage and Administration, Warnings and Precautions,
Adverse Reactions, Use in Specific Populations, Clinical
Pharmacology, Clinical Studies


Imatinib
(2)


Oncology


BCR-ABL1


Philadelphia
chromosome positive


Indications
and Usage, Dosage and Administration, Warnings and Precautions,
Adverse Reactions, Use in Specific Populations, Clinical
Pharmacology, Clinical Studies


Imatinib
(3)


Oncology


PDGFRB


PDGFR
gene rearrangement positive


Indications
and Usage, Dosage and Administration, Clinical Studies


Imatinib
(4)


Oncology


FIP1L1-PDGFRA


FIP1L1-PDGFRα
fusion kinase (or CHIC2 deletion) positive


Indications
and Usage, Dosage and Administration, Clinical Studies


Imipramine


Psychiatry


CYP2D6


CYP2D6
poor metabolizers


Precautions


Indacaterol


Pulmonary


UGT1A1


UGT1A1*28
allele homozygotes


Clinical
Pharmacology


Irinotecan


Oncology


UGT1A1


UGT1A1*28
allele carriers


Dosage
and Administration, Warnings and Precautions, Clinical
Pharmacology


Ivacaftor


Pulmonary


CFTR


CFTR
G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R,
R117H mutation positive, F508del mutation homozygotes


Indications
and Usage, Adverse Reactions, Use in Specific Populations,
Clinical Pharmacology, Clinical Studies


Ivacaftor
and Lumacaftor


Pulmonary


CFTR


CFTR
F508del mutation homozygotes


Indications
and Usage, Adverse Reactions, Clinical Pharmacology, Clinical
Studies


Lacosamide


Neurology


CYP2C19


CYP2C19
poor metabolizers


Clinical
Pharmacology


Lansoprazole


Gastroenterology


CYP2C19


CYP2C19
intermediate or poor metabolizers


Drug
Interactions


Lapatinib
(1)


Oncology


ERBB2


HER2
protein overexpression positive


Indications
and Usage, Dosage and Administration, Adverse Reactions, Use in
Specific Populations, Clinical Pharmacology, Clinical Studies


Lapatinib
(2)


Oncology


HLA-DQA1,
HLA-DRB1


HLA-DQA1*0201
or HLA-DRB1*0701 allele carriers


Clinical
Pharmacology


Lenalidomide


Hematology


del
(5q)


Chromosome
5q deletion positive


Boxed
Warning, Indications and Usage, Adverse Reactions, Use in Specific
Populations, Clinical Studies


Lesinurad


Rheumatology


CYP2C9


CYP2C9
poor metabolizers


Clinical
Pharmacology


Letrozole


Oncology


ESR1,
PGR


Hormone
receptor positive


Indications
and Usage, Adverse Reactions, Clinical Pharmacology, Clinical
Studies


Lomitapide


Endocrinology


LDLR


LDL
receptor mutation homozygotes


Indication
and Usage, Warnings and Precautions, Adverse Reactions, Clinical
Studies


Mafenide


Infectious
Diseases


G6PD


G6PD
deficient


Warnings,
Adverse Reactions


Mercaptopurine


Oncology


TPMT


TPMT
intermediate or poor metabolizers


Clinical
Pharmacology, Warnings, Precautions, Adverse Reactions, Dosage and
Administration


Methylene
Blue


Hematology


G6PD


G6PD
deficient


Precautions


Metoclopramide
(1)


Gastroenterology


CYB5R1-4


NADH
cytochrome b5 reductase deficient


Precautions


Metoclopramide
(2)


Gastroenterology


G6PD


G6PD
deficient


Precautions


Metoprolol


Cardiology


CYP2D6


CYP2D6
poor metabolizers


Clinical
Pharmacology


Mipomersen


Endocrinology


LDLR


LDL
receptor mutation heterozygotes and homozygotes


Indications
and Usage, Warnings and Precautions, Adverse Reactions, Use in
Specific Populations, Clinical Studies


Modafinil


Psychiatry


CYP2D6


CYP2D6
poor metabolizers


Clinical
Pharmacology, Precautions


Mycophenolic
Acid


Transplantation


HPRT1


HGPRT
deficient


Warnings
and Precautions


Nalidixic
Acid


Infectious
Diseases


G6PD


G6PD
deficient


Precautions,
Adverse Reactions


Nefazodone


Psychiatry


CYP2D6


CYP2D6
poor metabolizers


Precautions


Nilotinib
(1)


Oncology


BCR-ABL1


Philadelphia
chromosome positive


Indications
and Usage, Dosage and Administration, Adverse Reactions, Use in
Specific Populations, Clinical Pharmacology, Clinical Studies


Nilotinib
(2)


Oncology


UGT1A1


UGT1A1*28
allele homozygotes


Clinical
Pharmacology


Nitrofurantoin


Infectious
Diseases


G6PD


G6PD
deficient


Warnings,
Adverse Reactions


Nivolumab
(1)


Oncology


BRAF


BRAF
V600 mutation positive


Indications
and Usage, Adverse Reactions, Clinical Studies


Nivolumab
(2)


Oncology


CD274


PD-L1
protein expression positive


Clinical
Pharmacology


Nortriptyline


Psychiatry


CYP2D6


CYP2D6
poor metabolizers


Precautions


Obinutuzumab


Oncology


MS4A1


CD20
antigen positive


Clinical
Studies


Olaparib


Oncology


BRCA1-2


BRCA1-2
mutation positive


Indications
and Usage, Dosage and Administration, Warnings and Precautions,
Adverse Reactions, Clinical Pharmacology, Clinical Studies


Omacetaxine


Oncology


BCR-ABL1


Philadelphia
chromosome positive


Clinical
Pharmacology, Clinical Studies


Ombitasvir,
  Paritaprevir, Ritonavir, and Dasabuvir


Infectious
Diseases


IFNL3


IL28B
rs12979860 T allele carriers (non-C/C genotype)


Clinical
Studies


Omeprazole


Gastroenterology


CYP2C19


CYP2C19
poor metabolizers


Drug
Interactions


Osimertinib


Oncology


EGFR


EGFR
T790M mutation positive


Indications
and Usage, Dosage and Administration, Adverse Reactions, Clinical
Pharmacology, Clinical Studies


PEG-3350,
Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium
Ascorbate, and Ascorbic Acid


Gastroenterology


G6PD


G6PD
deficient


Warnings
and Precautions


Palbociclib
(1)


Oncology


ESR1


Estrogen
receptor positive


Indications
and Usage, Adverse Reactions, Clinical Pharmacology, Clinical
Studies


Palbociclib
(2)


Oncology


ERBB2


HER2
protein overexpression negative


Indications
and Usage, Adverse Reactions, Clinical Studies


Palonosetron


Gastroenterology


CYP2D6


CYP2D6
poor metabolizers


Clinical
Pharmacology


Panitumumab
(1)


Oncology


EGFR


EGFR
protein expression positive


Clinical
Pharmacology, Clinical Studies


Panitumumab
(2)


Oncology


KRAS


KRAS
codon 12 and 13 mutation negative


Indications
and Usage, Dosage and Administration, Warnings and Precautions,
Adverse Reactions, Clinical Pharmacology, Clinical Studies


Pantoprazole


Gastroenterology


CYP2C19


CYP2C19
poor metabolizers


Clinical
Pharmacology


Parathyroid
Hormone


Inborn
Errors of Metabolism


CASR


Calcium
sensing receptor mutation positive


Indications
and Usage, Clinical Studies


Paroxetine


Psychiatry


CYP2D6


CYP2D6
extensive and poor metabolizers


Drug
Interactions, Clinical Pharmacology


Pazopanib


Oncology


UGT1A1


UGT1A1*28
allele homozygotes


Clinical
Pharmacology, Warnings and Precautions


Pegloticase


Rheumatology


G6PD


G6PD
deficient


Contraindications,
Patient Counseling Information


Pembrolizumab
(1)


Oncology


BRAF


BRAF
V600 mutation positive


Indications
and Usage, Adverse Reactions, Clinical Studies


Pembrolizumab
(2)


Oncology


CD274


PD-L1
protein expression positive


Indications
and Usage, Dosage and Administration, Clinical Pharmacology,
Clinical Studies


Perphenazine


Psychiatry


CYP2D6


CYP2D6
poor metabolizers


Clinical
Pharmacology, Precautions


Pertuzumab


Oncology


ERBB2


HER2
protein overexpression positive


Indications
and Usage, Warnings and Precautions, Adverse Reactions, Clinical
Pharmacology, Clinical Studies


Phenytoin
(1)


Neurology


CYP2C9


CYP2C9
variant allele carriers


Clinical
Pharmacology


Phenytoin
(2)


Neurology


CYP2C19


CYP2C19
variant allele carriers


Clinical
Pharmacology


Phenytoin
(3)


Neurology


HLA-B


HLA-B*1502
allele carriers


Warnings


Pimozide


Psychiatry


CYP2D6


CYP2D6
poor metabolizers


Precautions,
Dosage and Administration


Ponatinib


Oncology


BCR-ABL1


Philadelphia
chromosome positive; T315I mutation positive


Indications
and Usage, Warnings and Precautions, Adverse Reactions, Use in
Specific Populations, Clinical Pharmacology, Clinical Studies


Prasugrel
(1)


Cardiology


CYP2C19


CYP2C19
poor metabolizers


Use
in Specific Populations, Clinical Pharmacology, Clinical Studies


Prasugrel
(2)


Cardiology


CYP2C9


CYP2C9
variant allele carriers


Use
in Specific Populations, Clinical Pharmacology, Clinical Studies


Prasugrel
(3)


Cardiology


CYP3A5


CYP3A5
variant allele carriers


Use
in Specific Populations, Clinical Pharmacology, Clinical Studies


Prasugrel
(4)


Cardiology


CYP2B6


CYP2B6
variant allele carriers


Use
in Specific Populations, Clinical Pharmacology, Clinical Studies


Pravastatin


Endocrinology


LDLR


LDL
receptor mutation heterozygotes and homozygotes


Indications
and Usage, Use in Specific Populations, Clinical Studies


Prilocaine
and Lidocaine (1)


Anesthesiology


CYB5R1-4


NADH
cytochrome b5 reductase deficient


Warnings
and Precautions


Prilocaine
and Lidocaine (2)


Anesthesiology


G6PD


G6PD
deficient


Warnings
and Precautions


Primaquine


Infectious
Diseases


G6PD


G6PD
deficient


Warnings
and Precautions, Adverse Reactions


Propafenone


Cardiology


CYP2D6


CYP2D6
poor metabolizers


Dosage
and Administration, Warnings and Precautions, Clinical
Pharmacology


Propranolol


Cardiology


CYP2D6


CYP2D6
poor metabolizers


Clinical
Pharmacology


Protriptyline


Psychiatry


CYP2D6


CYP2D6
poor metabolizers


Precautions


Quinidine


Cardiology


CYP2D6


CYP2D6
poor metabolizers


Precautions


Quinine
Sulfate (1)


Infectious
Diseases


G6PD


G6PD
deficient


Contraindications


Quinine
Sulfate (2)


Infectious
Diseases


CYP2D6


CYP2D6
poor metabolizers


Drug
Interactions


Rabeprazole


Gastroenterology


CYP2C19


CYP2C19
poor metabolizers


Drug
Interactions, Clinical Pharmacology


Rasburicase
(1)


Oncology


G6PD


G6PD
deficient


Boxed
Warning, Contraindications, Warnings and Precautions


Rasburicase
(2)


Oncology


CYB5R1-4


NADH
cytochrome b5 reductase deficient


Boxed
Warning, Warnings and Precautions


Rifampin,
Isoniazid, and Pyrazinamide


Infectious
Diseases


NAT1-2


NAT
1-2 slow acetylators


Clinical
Pharmacology, Adverse Reactions


Risperidone


Psychiatry


CYP2D6


CYP2D6
poor metabolizers


Clinical
Pharmacology


Rituximab


Oncology


MS4A1


CD20
antigen positive


Indications
and Usage, Dosage and Administration, Adverse Reactions, Use in
Specific Populations, Clinical Pharmacology, Clinical Studies


Rosuvastatin
(1)


Endocrinology


SLCO1B1


SLCO1B1
reduced function allele homozygotes


Clinical
Pharmacology


Rosuvastatin
(2)


Endocrinology


LDLR


LDL
receptor mutation heterozygotes and homozygotes


Indications
and Usage, Dosage and Administration, Adverse Reactions, Use in
Specific Populations, Clinical Pharmacology, Clinical Studies


Sevoflurane


Anesthesiology


RYR1


Ryanodine
receptor mutation positive


Warnings


Simeprevir


Infectious
Diseases


IFNL3


IL28B
rs12979860 T allele carriers (non-C/C genotype)


Clinical
Pharmacology, Clinical Studies


Sodium
Nitrite


Toxicology


G6PD


G6PD
deficient


Warnings
and Precautions


Sodium
Phenylacetate and Sodium Benzoate


Inborn
Errors of Metabolism


NAGS,
CPS1, ASS1, OTC, ASL, ABL2


Urea
cycle enzyme deficient


Indications
and Usage, Dosage and Administration, Warnings and Precautions,
Adverse Reactions, Drug Interactions, Use in Specific Populations,
Overdosage, Clinical Pharmacology, Clinical Studies


Sofosbuvir


Infectious
Diseases


IFNL3


IL28B
rs12979860 T allele carriers (non-C/C genotype)


Clinical
Studies


Succimer


Hematology


G6PD


G6PD
deficient


Clinical
Pharmacology


Sulfamethoxazole
and Trimethoprim


Infectious
Diseases


G6PD


G6PD
deficient


Precautions


Tamoxifen
(1)


Oncology


ESR1,
PGR


Hormone
receptor positive


Clinical
Pharmacology, Indications and Usage, Precautions, Adverse
Reactions


Tamoxifen
(2)


Oncology


F5


Factor
V Leiden carriers


Warnings


Tamoxifen
(3)


Oncology


F2


Prothrombin
G20210A allele positive


Warnings


Telaprevir


Infectious
Diseases


IFNL3


IL28B
rs12979860 T allele carriers (C/T and T/T genotype)


Clinical
Pharmacology, Clinical Studies


Tetrabenazine


Neurology


CYP2D6


CYP2D6
poor metabolizers


Dosage
and Administration, Warnings and Precautions, Use in Specific
Populations, Clinical Pharmacology


Thioguanine


Oncology


TPMT


TPMT
intermediate or poor metabolizers


Warnings,
Precautions, Dosage and Administration


Thioridazine


Psychiatry


CYP2D6


CYP2D6
poor metabolizers


Contraindications,
Warnings, Precautions


Ticagrelor


Cardiology


CYP2C19


CYP2C19
poor metabolizers


Clinical
Studies


Tolterodine


Urology


CYP2D6


CYP2D6
poor metabolizers


Warnings
and Precautions, Drug Interactions, Use in Specific Populations,
Clinical Pharmacology


Tositumomab


Oncology


MS4A1


CD20
antigen positive


Indications
and Usage, Clinical Pharmacology


Tramadol


Anesthesiology


CYP2D6


CYP2D6
poor metabolizers


Clinical
Pharmacology


Trametinib


Oncology


BRAF


BRAF
V600E/K mutation positive


Indications
and Usage, Dosage and Administration, Adverse Reactions, Clinical
Pharmacology, Clinical Studies, Patient Counseling Information


Trastuzumab


Oncology


ERBB2


HER2
protein overexpression or gene amplification positive


Indications
and Usage, Warnings and Precautions, Clinical Pharmacology,
Clinical Studies


Tretinoin


Oncology


PML-RARA


PML-RARα
translocation positive


Clinical
Pharmacology, Indications and Usage, Warnings


Trimipramine


Psychiatry


CYP2D6


CYP2D6
poor metabolizers


Precautions


Valproic
Acid (1)


Neurology


POLG


POLG
mutation positive


Boxed
Warning, Contraindications, Warnings and Precautions


Valproic
Acid (2)


Neurology


NAGS,
CPS1, ASS1, OTC, ASL, ABL2


Urea
cycle enzyme deficient


Contraindications,
Warnings and Precautions


Vemurafenib
(1)


Oncology


BRAF


BRAF
V600E mutation positive


Indications
and Usage, Dosage and Administration, Warnings and Precautions,
Clinical Pharmacology, Clinical Studies, Patient Counseling
Information


Vemurafenib
(2)


Oncology


NRAS


NRAS
mutation positive


Warnings
and Precautions, Adverse Reactions


Venlafaxine


Psychiatry


CYP2D6


CYP2D6
poor metabolizers


Precautions


Voriconazole


Infectious
Diseases


CYP2C19


CYP2C19
intermediate or poor metabolizers


Clinical
Pharmacology


Vortioxetine


Psychiatry


CYP2D6


CYP2D6
poor metabolizers


Dosage
and Administration, Clinical Pharmacology


Warfarin
(1)


Hematology


CYP2C9


CYP2C9
intermediate or poor metabolizers


Dosage
and Administration, Drug Interactions, Clinical Pharmacology


Warfarin
(2)


Hematology


VKORC1


VKORC1
rs9923231 A allele carriers


Dosage
and Administration, Clinical Pharmacology


Warfarin
(3)


Hematology


PROS1


Protein
S deficient


Warnings
and Precautions


Warfarin
(4)


Hematology


PROC


Protein
C deficient


Warnings
and Precautions


 
Share